Drug interactions & adverse reactions of relevance to dentistry (NW170215A)
Availability | Course has taken place | ||
Documents |
Need help viewing PDF documents? | ||
Subject | Bisphosphonates | ||
Description | Focusing on issues relevant to the dental team, to raise awareness of the laws that apply to medicines, | ||
Venue | North Manchester General Hospital, Manchester - Greater Manchester ![]() | ||
Date & time | Wednesday 15 February 2017, 09:30 to 12:30 | ||
Lecturer | Christine Randall ![]() | ||
Target audience | Recommended to all | ||
Development outcome | No development outcome | ||
Course style | Lecture![]() | ||
Core topic | Not a core topic | ||
Catering | Refreshments | ||
CPD hours | 3:00 | ||
Cost | £15.00 | ||
Aims | - To revise and update dental team members on dental pharmacology - To remind delegates about drug interactions of relevance to dentistry - To make those attending more able to deal with dental pharmacological issues and using current best practice | ||
Objectives | :- to manage and prescribe medicines within the current legal framework. :- Medicines and prescribing are highly regulated in the UK and knowing which aspects of the law are relevant to dental practice is essential. The session will cover: · The legal framework for medicines · Administration and supply of medicines privately and on NHS prescription - Patient Group Directions (PGDs) - Controlled drugs in dental practice e.g. midazolam. - to minimise risk to patients by raising awareness of drug interactions when prescribing and administering medicines. All medicines have the potential to cause or be affected by drug interactions. Some of the drug interactions that are clinically relevant and impact most in dental practice will be discussed. - to identify some important oral adverse drug reactions and report them appropriately to the Yellow Card Scheme. All medicines cause adverse effects – not in all patients and not always severe. Adverse drug reactions (ADRs) that may be seen by the dental team are highlighted including osteonecrosis of the jaw associated with bisphosphonates. Reporting ADRs is an important professional responsibility for all members of the dental healthcare team and how this should be done via the MHRAs Yellow Card Scheme will be described. - to recognise areas of concern when treating patients on medicines or using medicines to treat patients. Patients taking medicines can provide challenges for the dental team but sometimes appropriate use of commonly used medicines is also unclear, the following will be covered: · anticoagulants/antiplatelets including the new oral anticoagulants e.g. dabigatran · corticosteroids · lidocaine, maximum dose and contraindications analgesics, over the counter and prescribed | ||
Learning outcomes | - Appreciate the laws, guidance and legal constraints associated with assessing, prescribing and administering medicines. - Recognise and assess risks to patients associated with drug interactions when prescribing and administering medicines. - Identify oral adverse drug reactions, appreciate the value of the UK’s Yellow Card Scheme and to fulfil their professional responsibility to contribute appropriately to it. - Recognise and manage common areas of concern when treating patients on medicines or using medicines to treat patients. | ||